Advanz Pharma Corporation Ltd. (CXRXF)
Stock Price:
$4.00 USD
0.00 (0.00%)
Updated Sep 18, 2020 4:00 PM EDT - End of day
Key Info
| Market Cap |
195.65M |
| Revenue (ttm) |
503.46M |
| Net Income (ttm) |
-179.03M |
| Shares Out |
48.91M |
| EPS (ttm) |
-3.66 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Sep 18, 2020 |
| Last Price |
$4.00 |
| Previous Close |
$4.00 |
| Change ($) |
0.00 |
| Change (%) |
0.00% |
| Day's Open |
- |
| Day's Range |
3.98 - 4.10 |
| Day's Volume |
0 |
| 52-Week Range |
2.13 - 19.14 |
More Stats
| Market Cap |
195.65M |
| Enterprise Value |
n/a |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
48.91M |
| Float |
n/a |
| EPS (basic) |
n/a |
| EPS (diluted) |
-3.66 |
| FCF / Share |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
6,759 |
| Short Ratio |
10.40 |
| Short % of Float |
4.61% |
| Beta |
0.10 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
0.39 |
| PB Ratio |
11.64 |
| Revenue |
503.46M |
| Operating Income |
n/a |
| Net Income |
-179.03M |
| Free Cash Flow |
n/a |
| Net Cash |
n/a |
| Net Cash / Share |
0.00 |
| Gross Margin |
66.90% |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
1.41% |
| ROE |
-577.12% |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
15.5
Current: $4.00
High
15.5
Target: 15.50
*Average 12-month price target from 1 stock analysts.
Financial Overview
No financial data available for this stock yet.
Company Details
| Full Name |
Advanz Pharma Corporation Ltd. |
| Country |
United Kingdom |
| Employees |
429 |
| CEO |
Graeme Neville Duncan |
Stock Information
| Ticker Symbol |
CXRXF |
| Stock Exchange |
US OTC |
| Sector |
Healthcare |
| Industry |
Drug Manufacturers—Specialty & Generic |
| Unique Identifier |
OTCMKTS: CXRXF |
Description
ADVANZ PHARMA Corp., a specialty pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products. The company operates in two segments, ADVANZ PHARMA International and ADVANZ PHARMA North America. The ADVANZ PHARMA International segment owns or licenses a portfolio of branded and generic prescription products to wholesalers, hospitals, and pharmacies. This segment's products include Macrobid/Macrodantin to treat bladder infections, such as cystitis and urinary tract infections; Eltroxin, levothyroxine sodium that treats patients with an underactive thyroid gland; Fucithalmic, a topical gel treatment for patients suffering with a bacterial infection of the surface lining of the front of the eye; Zapain, a combination of codeine phosphate and paracetamol for severe pain reliefs, such as back pain, toothache, severe sprains and strains, and pain after operations. The ADVANZ PHARMA North America segment provides Donnatal, which is used as adjunctive therapy for irritable bowel syndrome; Zonegran, an anti-seizure drug indicated for adjunctive therapy in the treatment of partial seizures in adults with epilepsy; Nilandron for the treatment of metastatic prostate cancer; Plaquenil for the treatment of lupus and rheumatoid arthritis; and Photofrin for the treatment of certain types of cancer. The company sells its products through direct sales and local distribution relationships. The company was formerly known as Concordia International Corp. and changed its name to ADVANZ PHARMA Corp. in November 2018. ADVANZ PHARMA Corp. is headquartered in London, the United Kingdom.